Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression

Hepato-Gastroenterology

Volumn 59, Issue 120, 2012, Pages 2439-2444

  Dai, Guang Hai ^a   Shi, Van ^a   Chen, Li ^a   Lv, Ya Li ^a   Zhong, Mei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Docetaxel; Gastric cancer; HER2 amplification; HER2 positive; Trastuzumab

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84872077784     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12166     Document Type: Article

References (33)

1. Jørgensen JT: Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78:26-33.
2. Ohtsu A: Chemotherapy for metastatic gastric cancer: past, present, and future. Gastroenterology 2008; 43:256-264.
3. Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523-1529.
4. Scheurle D, Jahanzeb M, Aronsohn RS, Watzek L, Narayanan R: HER2/ neu expression in archival non-small cell lung carcinomas using FDA-approved Herceptin test. Anticancer Res 2000; 20:2091-2096.
5. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
6. Tokunaga A, Onda M, Okuda T, et al.: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75:1418-1425.
7. Pinto-de-Sousa J, David L, Almeida R, et al.: C-erbB-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Path 2002; 10:247-256.
8. Kim MA, Jung EJ, Lee HS, et al.: Evaluation of HER2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38:1386-1393.
9. Burstein HJ: The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353:1652-1654.
10. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4:361-370.
11. Kim SY, Kim HP, Kim YJ, et al.: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32:89-95.
12. Tanner M, Hollmén M, Junttila TT, et al.: Amplification of HER2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16:273-278.
13. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemoth Pharm 2007; 59:795-805.
14. Bang YJ, Van Cutsem E, Feyereislova A, et al.: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-697.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
16. Investigator's handbook: a manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment National Cancer Institute, [http://ctep.cancer.gov/investigatorResources/investigators- handbook.htm]
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-posirive breast cancer. N Engl J Med 2005; 353:1659-1672.
18. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
19. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al.: FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-820.
20. Joensuu H, Bono P, Kataja V, et al.: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27:5685-5692.
21. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapeuticplus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
22. Robert N, Leyland-Jones B, Asmar L, et al.: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786-2792.
23. Burstein HJ, Keshaviah A, Baron AD, et al.: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110:965-972.
24. Bartsch R, Wenzel C, Altorjai G, et al.: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25:3853-3858.
25. von Minckwitz G, du Bois A, Schmidt M, et al.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
26. Bekaii-Saab TS, Roda JM, Guenterberg KD, et al.: A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 2009; 8:2983-2991.
27. Safran H, Dipetrillo T, Akerman P, et al.: Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67:405-409.
28. McAlpine JN, Wiegand KC, Vang R, et al.: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009; 9:433.
29. Rebischung C, Barnoud R, Stefani L, Faucheron JL, Mousseau M: The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 2005; 8:249-252.
30. Inui T, Asakawa A, Morita Y, et al.: HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 2006; 260:484-487.
31. Leary A, Assersohn L, Cunningham D, et al.: A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol 2009; 64:455-462.
32. Giuliani F, Molica S, Maiello E, et al.: Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol 2005; 28:581-585.
33. Thuss-Patience PC, Kretzschmar A, Bichev D, et al.: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47:2306-2314.